DE69713485D1 - Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie - Google Patents

Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie

Info

Publication number
DE69713485D1
DE69713485D1 DE69713485T DE69713485T DE69713485D1 DE 69713485 D1 DE69713485 D1 DE 69713485D1 DE 69713485 T DE69713485 T DE 69713485T DE 69713485 T DE69713485 T DE 69713485T DE 69713485 D1 DE69713485 D1 DE 69713485D1
Authority
DE
Germany
Prior art keywords
thrombocytopenia
medicines
prevention
treatment
pth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69713485T
Other languages
English (en)
Other versions
DE69713485T2 (de
Inventor
Masahiko Tamura
Yasuhiro Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69713485D1 publication Critical patent/DE69713485D1/de
Publication of DE69713485T2 publication Critical patent/DE69713485T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seal Device For Vehicle (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Forklifts And Lifting Vehicles (AREA)
DE69713485T 1996-02-01 1997-02-03 Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie Expired - Lifetime DE69713485T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1670196 1996-02-01
PCT/JP1997/000255 WO1997027870A1 (fr) 1996-02-01 1997-02-03 Medicaments prevenant ou guerissant la thrombopenie

Publications (2)

Publication Number Publication Date
DE69713485D1 true DE69713485D1 (de) 2002-07-25
DE69713485T2 DE69713485T2 (de) 2003-01-30

Family

ID=11923601

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69713485T Expired - Lifetime DE69713485T2 (de) 1996-02-01 1997-02-03 Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie

Country Status (6)

Country Link
US (3) US6342477B1 (de)
EP (2) EP0878201B1 (de)
AT (1) ATE219374T1 (de)
AU (1) AU1558197A (de)
DE (1) DE69713485T2 (de)
WO (1) WO1997027870A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9904177A3 (en) 1996-09-26 2001-10-29 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
EP1004313B1 (de) 1997-05-15 2007-05-02 Chugai Seiyaku Kabushiki Kaisha Heilmittel für kachexie
AU5708500A (en) * 1999-07-02 2001-01-22 Chugai Seiyaku Kabushiki Kaisha Remedies for diseases caused by pth or pthrp
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
ATE309820T1 (de) * 1999-09-20 2005-12-15 Lilly Co Eli Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
WO2001082968A1 (fr) 2000-04-28 2001-11-08 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation cellulaire
CA2492295C (en) * 2002-07-25 2014-01-28 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
US7635477B2 (en) 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
AU2004242928B2 (en) * 2003-05-30 2011-03-10 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
JP5007427B2 (ja) * 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
EP1817056B1 (de) * 2004-11-11 2014-08-13 The General Hospital Corporation Parathyroidhormonrezeptoraktivierung sowie stamm- und vorläuferzellenausdehnung
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1961765A1 (de) * 2006-12-08 2008-08-27 Zealand Pharma A/S Verkürzte PTH-Peptide mit zyklischer Konformation
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
WO2010039872A1 (en) * 2008-10-01 2010-04-08 The Board Of Trustees Of The University Of Illinois Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1992000753A1 (en) * 1990-07-13 1992-01-23 The Regents Of The University Of California PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use

Also Published As

Publication number Publication date
ATE219374T1 (de) 2002-07-15
EP0878201A4 (de) 1999-11-10
EP1166796A3 (de) 2002-03-06
US7268110B2 (en) 2007-09-11
EP0878201A1 (de) 1998-11-18
US6342477B1 (en) 2002-01-29
EP1166796A2 (de) 2002-01-02
DE69713485T2 (de) 2003-01-30
AU1558197A (en) 1997-08-22
US6956022B2 (en) 2005-10-18
US20050197296A1 (en) 2005-09-08
EP0878201B1 (de) 2002-06-19
WO1997027870A1 (fr) 1997-08-07
US20020058626A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
ATE213390T1 (de) Wirkstoff zur erhöhung der produktion und der zucht von tieren in der geflügelindustrie
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
DE69000510T2 (de) Zusammensetzung fuer die behandlung von wasser oder waesserigen systemen.
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
ATE120612T1 (de) Unterdrückung des mercaptangeruches von organothiophosphatbioziden.
DE69227745T2 (de) Pharmazeutische Zusammensetzungen zur topischen Anwendung die ein Chelatierungsmittel, ein Tocopherol und einen antimikrobiellen Wirkstoff enthalten
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ZA916295B (en) Processes and agents for combating fleas
DE69838980D1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
ATE200026T1 (de) Behandlung von laminitis
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
SE8203054L (sv) Antihypertensivt medel
DE69114922T2 (de) Polysulfidverbindungen und Lipidperoxidierungsinhibitore, die diese Polysulfidverbindungen als aktive Zutaten enthalten.
UA23061A (uk) Композиція для лікуваhhя і профілактики ектопаразитарhих хвороб твариh
SE9202434D0 (sv) Skatolinaktiverande komposition
FI884041A (fi) Desinfiointikoostumus stafylokokkien tappamiseksi
EP0663211A4 (de) Mittel zur verhütung und behandlung von krankheiten der schleimhäute des verdauungstraktes.
ATE87211T1 (de) Heilpflanzengemisch fuer die behandlung von depressionen.
ATE79541T1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition